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Chapter 1: Introduction 
 1.1: Introduction to Trypanosoma brucei 
African trypanosomes are a protozoan parasite with the ability to cause 
disease in both humans and animals, rendering them an important subject 
of study. The human disease is called African sleeping sickness or Human 
African Trypanosomiasis (HAT) and the animal disease is animal 
trypanosomiasis or Nagana in cattle (Matthews et al. 2015). These diseases 
have a vast socioeconomic impact upon the African continent (Matthews et 
al. 2015). Infection occurs in mammalian hosts through the bite of the 
primary vector, the tsetse fly, which is found in the endemic area of sub-
Saharan Africa (Torr & Vale 2015).    
 
1.1.1 Life Cycle and Phylogeny 
 
 
Figure 1: The life cycle of Trypanosoma brucei gambiense and Trypanosoma 
brucei rhodesiense (human infective species). Other species infect other 
mammalian hosts (CDC 2015) 
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The life cycle of trypanosomes involves two stages, the vector stage and the 
mammalian host stage (Kennedy 2013). Infection of the host begins with the 
injection of metacyclic parasites by the tsetse fly during a blood meal 
(Figure 1). These metacyclic parasites then replicate in the tissue at the site 
of injection – this leads to a swollen ulceration at the area known as a 
chancre. Following this, the parasites will transform into a long and slender 
bloodstream form and enter the vascular system of the host, where they 
continue dividing (Kennedy 2013). Some of the parasites will then become a 
shorter, stumpy bloodstream form of parasite, which are pre-adapted to the 
tsetse environment and are taken up when a tsetse fly takes a bloodmeal to 
further the life cycle (CDC 2015). The vector stage begins with the ingestion 
of stumpy bloodstream forms in the bloodmeal by the tsetse fly. These then 
transform into procyclic form trypanosomes within the midgut of the fly, 
where they replicate by binary fission (Kennedy 2013). Some parasites 
transform into the proventricular non-dividing forms, which migrate to the 
salivary glands of the vector. Here they transform into epimastigotes, which 
are attached to the salivary glands and undergo more replication before 
transforming into the host infective metacyclic form of parasite, which are 
pre-adapted to life in the mammalian bloodstream and are then injected 
into the host by the fly, completing the cycle (Kennedy 2013).  
 
1.1.2 Vector: The Tsetse fly 
African trypanosomes infect their hosts through the bite of flies of the 
Glossina genus, known as tsetse flies (Steverding 2008). These flies are 
found in endemic regions of sub-Saharan Africa, where trypanosomes infect 
both cattle and humans, leading to disease (Torr & Vale 2015). The 
transmission of the two human infective sub-species of trypanosomes is 
associated with the presence of these flies, and as such, control of these 
flies has been considered as a preventative measure in the control of HAT 
(Barrett & Croft 2012). Vector control however, has been inadequate in the 
eradication of the disease, as it has proven difficult to completely eliminate 
the tsetse fly population – while instances of infection have been reduced, 
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they still occur, presumably due to the existence of an infection reservoir 
(Steverding 2008).  
 
1.2: Animal Trypanosomiases 
1.2.1 Animal infective strains of Trypanosoma 
There are three sub-species of Trypanosoma brucei, all of which are 
infective to non-human animals – however Trypanosoma brucei brucei rarely 
infects humans (Brun et al. 2010). Trypanosomes of this strain are lysed in 
human serum by trypanolytic factors, and therefore cannot infect humans 
(Uzureau et al. 2013). T. b. brucei, along with T. congolense and T. vivax, is 
the causative agent of animal trypanosomiasis, an infection of a wide range 
of mammalian hosts also known as Nagana, and causes substantial economic 
costs through loss of cattle (Steverding 2008). Trypanosoma brucei brucei is 
used as an animal model of human infective trypanosome infections, and is 
therefore key to understanding and treating both Nagana and HAT 
(Bucheton et al. 2011). 
 
1.2.2 Symptoms and Treatment 
Nagana is usually a chronic infection characterized by weight loss, oedema 
and listlessness of livestock; it can also affect the reproductive abilities of 
cattle, and commonly results in death of animals (Steverding 2008). The 
resultant loss of cattle affects farming in endemic regions, leading to 
economic impact on the country. Treatment of animal trypanosomiasis in 
Africa comes in the form of trypanocidal drugs which have been available 
for over 50 years – isometamidium, homidium and diminazene (Geerts et al. 
2001). The availability of these drugs has led to widespread treatment of 
cattle, however there has also been an increase in trypanosome drug 
resistance due to frequent misuse of these drugs in cattle (Geerts et al. 
2001). The emergence of trypanocide resistance has contributed to the 
resurgence of the disease (Delespaux & de Koning 2007) in both animal 
infections and human infections, and is therefore an important area of 
research. 
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1.3 Human African Trypanosomiasis 
1.3.1 T. b. gambiense and T. b. rhodesiense 
Two strains of Trypanosoma brucei infective to humans are T. b. gambiense 
and T. b. rhodesiense, which are separated geographically (Keating et al. 
2015). T. b. gambiense, the species responsible for a larger number of 
cases, is found in western Africa, and accounted for 96% of the reported 
cases in 2006 (Brun et al. 2010). T. b. rhodesiense is prevalent in eastern 
Africa and accounts for the remaining 4% of 2006 cases, which are more 
acute in nature than the T. b. gambiense infections (Brun et al. 2010).  
 
1.3.2 Symptoms 
Both human-infective species of African trypanosomes lead to symptoms 
occurring in two clear stages. The primary stage of infection is 
characterized by the appearance of flu-like symptoms, such as fever and 
headaches (Kennedy 2013). The secondary stage of infection is defined by 
the parasite invasion of the central nervous system (CNS), and leads to more 
severe symptoms, such as disturbed sleep (for which human infection earns 
its name, “sleeping sickness”), neurological disorders (Simarro et al. 2008; 
Brun et al. 2010), and if left untreated, eventually death.  
 
1.3.3 Diagnosis 
Current diagnosis of T. b. gambiense infection relies heavily on the 
screening for antibodies against a commonly expressed surface antigen on 
trypanosomes, a test known as the Card Agglutination Test for 
Trypanosomes (CATT) (Barrett & Croft 2012). The CATT test does however 
have its disadvantages – it can vary in sensitivity, it only detects T. b. 
gambiense, and it can sometimes give false negative results (Barrett & Croft 
2012; Chappuis et al. 2005). Following testing using the CATT assay, 
patients are diagnosed by the microscopic confirmation of parasites in the 
blood, lymph or CSF (Barrett & Croft 2012; Papadopoulos et al. 2004). 
Parasite numbers in human fluids can be low, however, and so false 
negatives can result in misdiagnosis, especially during infection with T. b. 
gambiense (Barrett & Croft 2012).  
	   10	  
 
1.3.4 Treatment 
Treatment of HAT relies on the use of four different drugs – pentamidine for 
the first stage of T. b. gambiense, and suramin for the first stage of T. b. 
rhodesiense, and melarsoprol for the second stage of both species 
(Babokhov et al. 2013). Suramin and pentamidine, while proven to have very 
effective trypanocidal qualities, are only effective while the infection is in 
the earlier stages – once the parasites cross into the CNS, leading to stage II 
infection, these drugs are ineffective (Babokhov et al. 2013).  Melarsoprol, 
which has been in use since 1949, is effective against second stage infection 
of both human infective subspecies of trypanosome (Babokhov et al. 2013). 
However, it also results in adverse and dangerous side effects – up to 10% of 
treated patients can end up suffering from an array of side effects such as 
seizures, dizziness, vomiting and fevers, and up to 5% of treated patients 
will subsequently die (Babokhov et al. 2013).  An additional drug, 
eflornithine, can be used during the second stage of T. b. gambiense 
infection (Simarro et al. 2008; Barrett & Croft 2012), however this also 
results in side effects such as vomiting, seizures and anaemia (Babokhov et 
al. 2013; Burri & Brun 2003). Even with these disadvantageous side effects, 
eflornithine is relatively well tolerated – and better still, since 2009, it can 
be given in tandem with nifurtimox in order to cure both stages of disease 
with even fewer side effects (Babokhov et al. 2013). Trypanosomal 
resistance to drug treatment remains a concern, and so looking to other, 
non-chemotherapy based strategies would be beneficial in eradicating the 
disease.  
 
1.3.5 Asymptomatic Patient Status 
It has been a widespread belief that human infection with African 
trypanosomes without treatment leads to death without exception, however 
there have been studies in recent years which would suggest that there 
exists asymptomatic patients. A 2012 study has shown natural asymptomatic 
patient status resulting in clearance in infection, and has acknowledged 
possible trypanotolerant patients as being important in understanding and 
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eradicating the disease (Jamonneau et al. 2012). In addition to this, these 
asymptomatic patients could act as perpetuators of disease foci, which 
could go someway to explaining why the eradication of HAT has been 
difficult so far.  
 
1.4 The Immune System 
1.4.1 The Innate Immune System 
The first barriers to a long lasting infection include both physical barriers 
such as the skin, and the components of the innate, non-adaptive immune 
system (Moens & Veldhoen 2012). These primary defences work in some 
cases to eradicate the invading pathogen, and in others to limit the spread 
or development of infection before the adaptive immune system can begin 
to work (Moens & Veldhoen 2012). 
Once a pathogen breaches the epithelia and enters the tissues of the host, 
it can be recognized by tissue resident phagocytes known as macrophages 
and dendritic cells (Malissen et al. 2014). These phagocytes can broadly 
recognize pathogenic motifs (PAMPs) through pathogen recognition 
receptors (PRRs), and can subsequently ingest and destroy many invaders 
(Kay et al. 2013). Recognition of pathogens by macrophages leads to 
phagocytosis, in tandem with the production and release of cytokines and 
toxic products such as antimicrobial peptides and nitric oxide (Kay et al. 
2013). The release of inflammatory mediators from phagocytes results in 
local inflammation, which induces the migration of cells to the site of 
infection – cells such as neutrophils, monocytes (which then differentiate 
into more macrophages), eosinophils, and eventually lymphocytes (Mosser & 
Edwards 2008). Recognition of invading pathogens by dendritic cells (DCs), 
however, can result in the processing of antigen within the cells. Upon 
antigen recognition, DCs will ingest the pathogen, and migrate to the lymph 
nodes in order to initiate the adaptive immune response (Wang et al. 2015). 
DCs therefore act as a bridge between the innate and adaptive immune 
response, allowing for the specific responses required to eradicate 
infections (Wang et al. 2015).  
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1.4.2 The Adaptive Immune System 
While the innate immune system does broadly recognize invading 
pathogens, it is limited to the destruction of pathogens expressing specific 
pathogenic motifs (Kay et al. 2013) . In order to effectively defend the host 
organism, the adaptive immune system has developed in such way that its 
lymphocytes can recognize and act against a vast array of antigens, while 
also providing long lasting defence through the generation of immunological 
memory (Reinherz 2015). As previously mentioned, DCs will ingest and 
process antigen, leading to the presentation of antigen to lymphocytes 
within the lymph nodes (Wang et al. 2015).   
The two chief populations of lymphocytes are B and T lymphocytes, and 
both express antigen receptors of vast specificities (Reinherz 2015) in order 
to induce as specific and direct an immune response as possible. DCs 
present antigen to T lymphocytes in an indirect fashion; antigen is bound to 
cell surface expressed MHC molecules, which allows the T cells to 
distinguish between self-expressed host antigens and invading pathogenic 
antigens (Luckheeram et al. 2012). Activation of T cells can then promote 
the activation of B cells through the secretion of cytokines – this leads to 
the B cell production of antigen specific molecules known as 
immunoglobulins (Ig) (Luckheeram et al. 2012). It can also result in class 
switching of the immunoglobulin molecules – allowing the Ig molecules to 
maintain their specificity but alter their function, and enabling their binding 
to their specific antigen, targeting the antigen for degradation by the 
immune system (Ollila & Vihinen 2005). 
  
1.5 T lymphocytes 
1.5.1 Recognition of Antigen 
T lymphocytes recognize antigen through the heterodimeric receptor 
complex on the cell surface, known as the T cell receptor (TCR) 
(Luckheeram et al. 2012). The recognition of antigen through this receptor 
is limited to antigens bound to major histocompatibility (MHC) molecules, 
allowing the T cell to distinguish between self and non-self antigens as 
previously noted (Eckle et al. 2013). In the case of CD4+ T cells, recognition 
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is restricted to antigens expressed on MHCII molecules on antigen presenting 
cells (APCs), while CD8+ T cells recognize antigen bound to MHCI molecules 
on APCs (Artyomov et al. 2010). Dendritic cells, macrophages and B cells 
can present antigen to T cells, with dendritic cells being considered the 
most important and efficient of the APCs. Binding of the TCR to the MHC-
antigen complex results in a signal transduction within the T cells, leading 
to their activation and subsequent effector functions (Luckheeram et al. 
2012).  
 
1.5.2 Activation 
Activation of CD4+ T cells occurs, as previously described, through 
recognition of a peptide-MHC complex on an APC. Again, as mentioned, 
CD4+ T cells recognize those antigens presented on MHCII molecules, to 
which the CD4 co-receptor binds. These APCs must then interact with naïve 
T cells in two further ways in order to effectively drive activation and 
effector functions (Elias et al. 2005).  
 
 
 
Figure 1: 3-signal activation model of CD4+ T cells by APCs. Signal 1: the recognition of 
antigen-MHCII complex by TCR. Signal 2: Costimulation by CD28 binding with B7. Signal 
3: cytokines in extracellular environment promote effector differentiation (Elias et al. 
2005) 
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A second, costimulatory signal is then given to the T cell by the APC – the 
most well known of these signals comes from the B7 molecule family 
(Sharpe & Freeman 2002). B7 molecules bind to CD28, a surface molecule of 
T cells, resulting in the appropriate clonal expansion of T cells, or if 
necessary, inhibition of T cell activation (Chen & Flies 2012). A third 
activation signal can then determine the effector function of the responding 
T cell – cytokines released by the presenting APC into the surrounding 
environment drive the T cell to differentiate into a context dependent 
effector cell (Cosmi et al. 2014; Yamane & Paul 2012). 
 
1.5.3 Inhibition 
Prolonged inflammation can lead to autoimmunity, and therefore it is 
critical that the immune system has within it systems of regulation. This 
occurs in T lymphocytes through the ligation of molecules to inhibitory 
receptors on the cell surface (Chen & Flies 2012). CTLA-4 is one of these 
inhibitory receptors, homologous to the co-stimulatory CD28 molecule 
previously described, and competitively binds to the B7 molecules on the 
APC (Parry et al. 2005). This ligation results in a signal transduction that will 
inhibit T lymphocyte activation. Abatacept, a CTLA-4 fusion with IgG, is a 
drug used to prevent T cell activation in the treatment of rheumatoid 
arthritis (Moreland et al. 2006), and has been studied as a possible therapy 
in a number of other autoimmunities. It binds to the B7 molecules on the 
APCs, halting their ability to activate T cells (Moreland et al. 2006). PD-1 is 
another inhibitory receptor, expressed both by T and B cells, and upon 
other cells of the immune system (Parry et al. 2005; Fife & Pauken 2011). 
Its ligands are found constitutively expressed throughout the body, and are 
upregulated during periods of inflammation (Merelli et al. 2014). Expression 
of PD-1 on T cells has also been discussed as being an indicator of 
lymphocyte exhaustion, and is upregulated during chronic infections (Day et 
al. 2006; Wherry 2011). 
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1.5.4 Exhaustion 
During a chronic infection, the long term activation of T cells can result in 
the exhaustion of lymphocytes – this is characterized by diminished effector 
function, and shows phenotypically as a continued expression of inhibitory 
receptors such as PD-1 and LAG-3 (Wherry 2011). These exhausted cells can 
be considered a state of T cell differentiation before their deletion. 
Continuous exhaustion of T cells during a chronic infection can have a 
detrimental effect on the immune response, and can hamper the efforts to 
control or clear infection. Keeping this in mind, blocking of inhibitory 
receptors as a therapy in some chronic infections has been researched 
(Butler et al. 2012; Day et al. 2006), and could be useful in reawakening the 
immune system to fight infection.   
 
1.5.5 CD4+ T lymphocytes 
 (i) Effector Functions 
CD4+ T cells, or T helper cells, function primarily to help other cells of the 
immune system carry out their functions during an immune response – such 
as activating innate immune cells, or switching the class of antibody that a 
B cell produces (Crotty 2015). Each CD4+ T cell subset has a slightly 
different function and therefore different methods by which they help these 
other cells, to coincide with the different types of pathogens that a host 
organism can face (Luckheeram et al. 2012).  
 
TH1 effector cells are generated in order to eliminate intracellular 
pathogens (Luckheeram et al. 2012). They primarily produce IFN-γ – this 
helps the immune response by promoting further activation of macrophages 
and other phagocytes, enhancing their ability to degrade invaders (Cosmi et 
al. 2014). TH1 cells also secrete IL-2, which induces proliferation of both 
CD4+ T cells and CD8+ T cells, further augmenting the efficiency of the 
response (Yamane & Paul 2012).  
 
While TH1 cells fight intracellular pathogens, TH2 cells are made available to 
combat extracellular pathogens, such as parasitic helminthes, and secrete 
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cytokines such as IL-4, IL-5, IL-9, IL-10 and IL-13 (Cosmi et al. 2014). A TH2 
response also results in the degranulation of mast cells, and the activation 
of other innate immune cells such as eosinophils and basophils (Luckheeram 
et al. 2012). The secretion of IL-10 actively suppresses any TH1 responses 
that could occur, allowing for the maintenance only of the appropriate 
response while limiting any damage to the host tissue (Moore et al. 2001).  
 
Table 1: Effector T cell subsets, the cytokines they secrete and their 
functions within the immune response (Luckheeram et al. 2012). 
 
As with TH2 cells, TH17 cells are required for the eradication of extracellular 
pathogens, this time fungi and other bacteria (Luckheeram et al. 2012). As 
their name suggests, they mainly produce cytokines from the IL-17 family 
along with IL-21 (Luckheeram et al. 2012). This promotes a pro-
inflammatory environment by interacting with the IL-17R on multiple cell 
types throughout the host.  
Effector T Cell Subset Cytokines Produced Functions 
TH1 
 
IFN-γ, IL-2 
Elimination of 
intracellular pathogens 
– bacteria and protozoa 
TH2 
IL-4, IL-5, IL-9, IL-10, 
IL-13 
Destruction of 
extracellular parasites – 
e.g. parasitic 
helminthes. Also 
contribute to allergy 
TH17 
IL-17A, IL-17F, IL-21, IL-
22 
Eradication of 
extracellular bacteria 
and fungi 
TREG TGF-β, IL-10, 1L-35 
Negative regulators of 
immune responses 
CD8+ TNF-α, IFN-γ 
Destroy intracellular 
pathogens such as 
viruses 
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Regulatory T cells function as negative regulators of the immune system, to 
return the environment to homeostasis and prevent any autoinflammation. 
It carries this function out through the production of anti-inflammatory 
cytokines such as TGF-β, IL-10 and IL-35 (Luckheeram et al. 2012).  
 
1.5.6 CD8+ T lymphocytes 
 (iii) Effector Functions 
CD8+ T lymphocytes, or cytotoxic T cells as they are otherwise known, 
recognize antigen presented on MHCI molecules, which are expressed 
ubiquitously throughout the host, upon all nucleated cells (Wong & Pamer 
2003). Similar to TH1 cells, they work to eradicate intracellular pathogens 
such as viruses (Novais & Scott 2015). They can do this through the secretion 
of TNF-α and IFN-γ, the controlled release of cytotoxic granules into the 
affected cells, or through induced apoptosis of the target cells (Harty et al. 
2000).  
 
1.6 The Immune Response to Trypanosomes 
1.6.1 The Innate Response to Trypanosomes 
(i) Human Serum Trypanolytic Factors 
Human blood serum contains within it multiprotein high density lipoprotein 
complexes which act as trypanolytic factors (TLF1 and TLF2) (Raper et al. 
1999). Parasites must overcome destruction by these complexes in order to 
fully establish long-term infection. As such, these TLFs confer resistance in 
humans and in some primate species to most of the trypanosomes, except 
those which have evolved to evade killing by them – T. b. gambiense and T. 
b. rhodesiense (Raper et al. 1999).  
Both TLFs contains apolipoproteins L-1 (apoL1) and haptoglobin-related 
protein (HPR), which act in tandem to allow destruction of the parasite. 
TLF2 also contains IgM (Raper et al. 1999). The human infective strains have 
developed different ways to avoid this innate immune defence – T. b. 
gambiense expresses Trypanosoma gambiense-specific glycoprotein (TgsGP), 
which was found to be essential in parasite resistance to host TLFs 
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(Capewell et al. 2013). TgsGP expression leads to prevention of apoL-1 
function within the parasites and consequent parasite evasion of death 
(Uzureau et al. 2013). In the case of T. b. rhodesiense, human serum 
resistance is attributed to the expression and transcription of a gene called 
the serum resistance associated (SRA) gene (Capewell et al. 2014), which 
interferes with the apoL-1 within the trypanosome lysosome and 
subsequently prevents parasite death.  
 
(ii) PAMP recognition 
Pathogen-associated molecular patterns (PAMPs) in trypanosome infections 
can come from trypanosomal components. Recognition of these components 
by the PRRs of the innate immune cells is crucial in the induction of a quick 
and effective immune response. The glycosyl-inositol-phosphate (GIP) 
residue attached to soluble variable surface glycoprotein (sVSG) acts as one 
of these PAMPs and activates macrophages through a protein tyrosine kinase 
signal transduction pathway (Tachado & Gerold 1997), prompting the 
release of the pro-inflammatory TNF-α (Magez et al. 1998). Membrane 
bound VSG has also been noted to have macrophage activating capacities, 
through the glycophosphatidylinositol (GPI) anchor, however this stimulation 
results in the secretion of IL-1α and responsiveness to LPS (Magez et al. 
1998). In either case, recognition of GIP or GPI moieties results in the 
activation of pro-inflammatory macrophages.  
Detection of trypanosomal DNA can also result in the activation of the 
innate immune system (Harris et al. 2006) through the ligation of 
trypanosomal CpG DNA with macrophage Toll-like receptor (TLR) 9. This 
response was demonstrated to be important to host survival through an 
increased resistance to infection in mice following artificial stimulation 
through TLR9 (Harris et al. 2007). Exposure of these PAMPs to their ligands 
on innate immune cells, particularly macrophages, can enhance both the 
innate and adaptive response to infection. 
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(iii) Macrophage activation 
The bite of a tsetse fly results in a localized inflammatory response, 
distinguished by invasion of the area by macrophages, granulocytes and 
lymphocytes as a result of the replicating parasites (Naessens & Mwangi 
2003). Activation of macrophages in response to trypanosomal components, 
as previously described, can result in a strong TH1 response. The production 
of cytokines such as IL-12, IL-6, TNF-α and IL-1 lead to a pro-inflammatory 
response defined by the production of macrophage-derived trypanocidal 
molecules, such as reactive nitrogen oxide species (RNOS) and reactive 
oxygen intermediates (ROIs) (Paulnock et al. 2010). These secreted 
molecules prove to be destructive to the trypanosomes. TNF-α in particular 
has been discussed as having a detrimental effect on parasite growth within 
the blood of a mammalian host – mice with disrupted TNF-α genes show 
higher levels of blood parasitemia than control mice (Magez & Radwanska 
1999). The activation of these macrophages works as a positive feedback 
loop – degradation of parasites leads to the availability of more PAMPs, 
allowing for further parasite recognition and subsequently more macrophage 
activation, which initiates a robust adaptive immune response. 
 
1.6.2 The Adaptive Immune Response to Trypanosomes 
(i) TH1 Response 
As previously alluded to, the activation of innate cells such as macrophages 
and dendritic cells results in the production of IL-12 and IL-18. This can aid 
the activation of the adaptive immune response, and polarizes this response 
in favour of a TH1 effector response (Perito et al. 1992; Mansfield & 
Paulnock 2005). The resultant IFN-γ from the T cells further activates the 
macrophages, thereby propagating a continuously activated immune 
response to the parasites. This IFN-γ production has been discussed as being 
both IL-12 dependent and also crucial to the resistance of mice to infection 
(Hertz et al. 1998; Barkhuizen et al. 2007), suggesting that a TH1 effector 
response is important in the response to trypanosome infection. 
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(ii) B cells and Antibodies 
B cells have been shown to be necessary to survival of trypanosome 
infection through the infection of B cell deficient mice (Magez et al. 2008), 
which could suggest the production of antibodies to be crucial to 
trypanosomiasis resistance. IgM antibodies have been considered to be the 
first humoral line of defence against parasites, with isotype switching 
occurring in response to specific T cell responses (Radwanska et al. 2008). 
The generation of antibodies in response to parasite antigens has been 
shown to be stage specific. During the first few days of Trypanosoma brucei 
brucei infection, immunoglobulin (Ig) isotypes IgG2a and IgG2b are 
prevalent – however, during later stages of infection, these give way to T-
cell dependent IgG1 and IgG3 antibody responses, while maintaining 
constant IgM respsonses. (Radwanska et al. 2000).  Similarly, infection of 
mice with Trypanosoma brucei rhodesiense results in immunoglobulin class 
switching to IgG1, IgG2a and IgG3, however IgA and IgE antibodies were not 
induced (Schopf & Filutowicz 1998). During infection however, it has been 
noted that B cells are depleted following a period of polyclonal activation 
and subsequent exhaustion (Bockstal et al. 2011). This contributes to 
progression of infection through a lessened host ability to generate 
antibodies against the trypanosomes (Bockstal et al. 2011). Studies in 
humans, however, suggest that B cell depletion is not as much a problem as 
in experimental mouse models – however the authors do note that these B 
cells may lack some functionality, which they could not test (Lejon et al. 
2014). 
 
 
1.7 Evasion of the Immune Responses by African Trypanosomes 
1.7.1 Antigenic variation 
Trypanosomes have had to evolve in order to evade the host immune 
response. One such method of defence is the variation of the variable 
surface glycoprotein (VSG), a homodimeric antigen which is densely present 
on the surface of the trypanosome (Pays et al. 2004). These antigens 
protect the surface of the parasite from the immune system of the host, by 
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hiding and preventing adaptive immune responses to the invariable surface 
antigens present there (Pays et al. 2004).Trypanosomes are able to undergo 
genetic switching in order to vary the VSG that they present – while they 
present one VSG at a time, they stochastically alter it through genetic 
switching mechanisms (Robinson et al. 1999). This allows for the persistence 
of infection, as while antibodies are generated against specific VSGs, other 
parasites within the host will already be expressing other variants, allowing 
for the survival of the species despite the host humoral responses. T. b. 
brucei alone has 806 VSG genes, some of which are psuedogenes used to 
create mosaic VSG genes and further enhancing the variablility (Berriman et 
al. 2005). As the VSGs are shielding the invariant genes, they have been 
effective in hindering the progress of trypanosome vaccine development, 
and allowed for persistence of disease in mammals.  
 
1.7.2 B and T cell suppression 
Following evasion of the immune system, Trypanosoma brucei brucei also 
alters the immune response, suppressing the adaptive response through 
alteration of macrophage function (Namangala et al. 2000). Specifically, 
macrophage ability to present antigens using MHCII molecules is lessened, 
and the macrophages produce immunosuppressive mediators such as IL-10 
which can impact directly upon lymphocyte activation (Namangala et al. 
2000). Further studies have also shown a mucin of Trypanosoma cruzi to be 
an inhibitor of CD4+ T cell function (Nunes et al. 2013) and this inhibition 
has been suggested to further disease progression. There has also been data 
showing a similar suppression of B cells, also during Trypanosoma cruzi 
infection, which would again further disease progression through lower 
numbers of antibodies generated (Zuñiga et al. 2000). Additionally, B cells 
have been shown to be depleted following activation and exhaustion in 
experimental models of Trypanosoma brucei brucei (Bockstal et al. 2011), 
and this has been discussed recently to be dependent upon IFN-γ (Cnops et 
al. 2015). A similar situation has been noted in chronic human malarial 
infection, where both B and T lymphocytes have been shown to be 
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functionally exhausted (Illingworth et al. 2013).  
 
1.7.3 Alteration of antigen presenting cell functions 
It has been discussed in previous studies that one aspect of immune evasion 
employed by trypanosomes is the alteration of APC functions. A study 
published in 2000 suggested that trypanosomes induce a decrease in MHCII 
expression in macrophages, thereby decreasing their ability to activate T 
cells, and lessening the chance of an effective adaptive response 
(Namangala et al. 2000). Further studies demonstrated that during 
infection, APCs had a reduced capacity for the presentation of new VSG 
antigen (Dagenais et al. 2009) – this study also showed that susceptible 
animals suffered from depletion of splenic DC populations, which had been 
proven to be important in generation of an effective TH1 response. 
 
1.8 Polyclonal Lymphocyte Activation  
1.8.1 Leishmania and malaria 
Polyclonal lymphocyte activation and subsequent exhaustion has been 
reported in a number of chronic infections (Day et al. 2006; Zajac et al. 
1998; Brooks et al. 2005). This has also been noted in parasite infections. 
During the blood stage of malarial infections, B and T cells are polyclonally 
activated, before showing phenotypic characteristics of exhaustion and 
dying by apoptosis (Illingworth et al. 2013; Butler et al. 2012; Muxel et al. 
2011). The increased expression of exhaustion markers PD-1 and LAG-3 on 
CD4+ T cells during Plasmodium falciparum infection led to further study in 
in vivo models (Butler et al. 2012).  Blocking these inhibitory markers on 
CD4+ T cells during Plasmodium yoelii infection in mice resulted in the 
clearance of parasites from the blood of the host, suggesting that the 
phenotypic exhaustion of T cells aids parasite survival (Butler et al. 2012). 
The comparable increase in inhibitory marker expression in humans suggests 
that this could be an avenue of treatment for malaria through restoration of 
CD4+ T cell function (Butler et al. 2012).  Similarly, non-specific activation 
of B and T lymphocytes occurs during visceral leishmaniasis, resulting in a 
pro-inflammatory response which is thought to contribute to the 
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immunopathogensis of the disease (Santos-Oliveira & Da-Cruz 2012). This is 
also followed by a depletion of lymphocytes during infection.  
 
1.8.2 Trypanosomes 
The polyclonal activation of both B and T lymphocytes is also a hallmark of 
infection with trypanosomes of the Trypanosoma cruzi species (Gao & 
Pereira 2001), and has been discussed as occurring in order to benefit 
parasite survival within the host. Activation of lymphocytes leads to 
exhaustion during chronic infection (Wherry 2011), and could contribute to 
the immunosuppression seen in trypanosome infections – leading also to the 
development of secondary infections. Studies have shown that a 
neuraminidase expressed by T. cruzi enhances both mitogenic and antigenic 
T cell activation (Gao & Pereira 2001), through polyclonal activation of B 
cells. As previously described above, similar levels of lymphocyte activation 
can be seen in malaria and leishmania, which could suggest that the 
exhaustion of T lymphocytes during infection works in favour of parasite 
survival. If true, this could lead to the development of new therapeutics 
against trypanosome infection and better understanding of the parasite, 
leading eventually to absolute eradication to the benefit of the African 
continent.  
 
1.9 Aims of the thesis 
Overall, this project aims to further characterize the CD4+ T cell response 
to trypanosome infection. In doing so, it is hoped that this will lead to a 
better understanding of how the infection progresses and eventually to the 
investigation of new treatment strategies. The project has two main routes 
of investigation: in vivo characterization of CD4+ cell response to infection, 
and the development of an in vitro assay to replicate this in vivo response.  	  	   	  
	   24	  
Chapter 2: Materials and Methods 
2.1 Animals 
2.1.1 Infection of animals with T.b.brucei 
Mice were used in accordance with local and Home Office regulations. 
Female Balb/c mice, aged 8 to 10 weeks were used for infection. Frozen 
stabilates of T.b.brucei clones were grown in Balb/c mice before initiating 
experimental infections. Strains of Trypanosoma brucei used throughout 
these experiments were Trypanosoma brucei brucei STIB 247 and TREU 927, 
and Trypanosoma brucei gambiense PA44. These donor mice were 
immunosuppressed by cyclophosphamide treatment (0.25µg/g, Sigma) 24 
hours before intraperitoneal injection with trypanosomes. Animals were 
exsanguinated, and parasite number was counted using a haemocytometer. 
Blood was then diluted with phosphate-buffered saline (PBS) containing 1% 
glucose (PBS-G) to give 104 parasites in 200µl. 10-week old female Balb/c 
mice were then infected by an intra peritoneal injection of 200µl of 104 
parasites. The infection was monitored through assessment of weight, blood 
parasitemia, and general health until their cull.  
 
2.1.2 Monitoring parasite burden  
Blood parasite burden was measured daily by venipuncture and parasite 
counts as instructed by Herbert and Lumsden 1976 (Herbert & Lumsden 
1976). Health was also assessed by weights and mouse 
behaviour/appearance.  
 
2.2 In vivo treatment of mice 
2.2.1 Abatacept treatment of mice 
Abatacept was provided by Bristol-Myers Squibb and was administered at a 
dose of 10mg/kg intraperitoneally every second day from the day before 
infection. A human IgG1 was used as a control fusion protein. 
 
2.2.2 PD-L1 and LAG-3 treatment of mice 
Anti-mouse LAG-3 and anti-mouse PD-L1 in vivo monoclonal antibodies were 
acquired from BioXCell. Both antibodies were administered via 
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intraperitoneal injection in a single volume of 200µl containing 200µg of 
each every 2 days from day 5 post-infection. Rat IgG was used as an isotype 
control. 
 
2.3 Fluorescence activated cell-sorting analysis (FACs) 
2.3.1 Preparation of spleen for FACs 
Spleens were mechanically disrupted and filtered through a Falcon® 40µm 
cell strainer (Corning), and the resulting cell suspension transferred to 15ml 
tubes. These were then washed by centrifugation at 400g for 5 minutes, the 
supernatant discarded, and the pellet resuspended in the little remaining 
volume. 5ml of 1X red blood cell (RBC) lysis buffer (eBioscience) was added 
to the cell suspension and incubated on ice for 4 minutes. Cells were 
washed twice using PBS and transferred to FACs tubes.  
 
2.3.2 Preparation of lymph nodes for FACs 
Lymph nodes were mechanically disrupted in PBS using a nylon 
monofilament filter fabric (45microns, Cadisch Precision Meshes) and the 
cell suspension transferred to 15ml tubes, which were centrifuged at 400g 
for 5 minutes. Discarding the supernatant, the cells were then resuspended 
in 1ml of PBS and transferred to FACs tubes.  
 
2.3.3 Preparation of blood for FACs 
Blood was centrifuged at 3000rpm for 10 minutes. Supernatant was 
collected and frozen for future assays. 4ml of RBC lysis buffer was added to 
the cells and incubated on ice for 5 minutes. Following this, cells were 
washed twice with PBS, resuspended in 1ml of PBS and transferred to FACs 
tubes.  
 
2.3.4 Cell Staining for FACs analysis 
200µl of cells from blood, inguinal lymph nodes and spleen single cell 
suspensions were incubated at 4°C in 100µl Fc block with mouse serum for 
20 minutes, and then with anti-mouse ICOS-, CD4-, LAG-3- and PD-1-
fluorochrome-conjugated antibodies for 30 minutes. The cells were then 
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washed, and fixed by incubation with 1% paraformaldehyde for 20 minutes. 
Cell marker expression was analysed on a MACSquant (Miltenyi) and 
subsequently analysed using FlowJo software. Unstained cells were used as 
controls for auto-fluoresence.  
 
2.4 In vitro culture of bloodstream T.b.brucei 
2.4.1 Culturing bloodstream T. b. brucei 
T. brucei strain STIB 247 bloodstream form parasites were cultured in HMI-9 
medium, supplemented to 20% (v/v) Serum plus. Parasites were maintained 
at a density of roughly 105-106 parasites per ml in a vented lid flask at 37oC, 
5% CO2 incubator. Cultures were passaged every 2-3 days to prevent from 
overgrowing.  
Figure 4: Example of gating strategy from in vitro assay. Cells were gated 
on a lymphocyte phenotype – small, non-granular cells. Cells were then 
assessed on FSC-H against FSC-A to gate upon single cells. Within this, 
cells were then gated on viability and CD4 expression, before being 
analysed for ICOS and LAG-3 expression.  
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2.5 Co-culture of splenocytes with parasites 
2.5.1 Preparation of splenocytes for culture 
Spleens were removed from naïve Balb/c mice and prepared for FACs as 
previously described. Cells were then counted and resuspended at 5 x 106 
cells/ml, before being plated out on 96-well plates at 5 x 105 cells/well in 
100µl and maintained in a 37°C, 5% CO2 incubator. 
2.5.4 Addition of Concanavalin A (ConA) for full and sub-optimal stimulation 
Following plating of cells in 100µl of media to wells of a 96-well plate, 100µl 
of media containing experimental conditions was added. Positive control 
wells received an extra 100µl of media containing 5µg/ml ConA, bringing the 
final concentration in each well to 2.5µg.ml. Sub-optimal stimulation 
control wells received 100µl of media containing 0.2µg/ml ConA, bringing 
the final concentration to 0.1µg/ml. Trypanosome control wells received 
100µl of media containing 105 trypanosomes. Experimental wells received an 
addition 100µl of media containing 0.2µg/ml ConA and 105 trypanosomes. 
Plates were incubated for up to 72 hours in a 37°C, 5% CO2 incubator. 
 
2.5.5 Preparation of in vitro co-culture for FACs 
Cells and supernatant were transferred into FACs tubes and centrifuged at 
400g for 5 minutes. They were then incubated at 4°C in Fc block with mouse 
serum for 20 minutes, and then with ICOS-, CD4-, LAG-3- and PD-1-
fluorochrome-conjugated antibodies for 30 minutes. The cells were then 
washed and analysed on a MACSquant (Miltenyi) and subsequently analysed 
using FlowJo software. 
 
2.6 Statistics 
Data was analysed using GraphPad Prism® software. To compare the means 
of two or more samples, an ANOVA test was used. Where two independent 
variables were present, two-way ANOVA was carried out. P values < 0.05 
were considered to be significant . 
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Chapter 3: Results – CD4+ T cell Activation During Murine T.b.brucei 
Infection 
3.1 Introduction and Aims 
Different methods of immune manipulation by trypanosomes have been 
reported and described previously in this thesis – these methods can allow 
the parasite to effectively evade the adaptive immune system. Prior to the 
immunosuppression that characterizes trypanosome infection comes a 
period of massive polyclonal lymphocyte activation (Aksonas & Bancroft 
1984; Bockstal et al. 2011; Olsson et al. 1991), meaning that many T cells of 
many different TCR specificities are being activated at one time. This 
generates a non-antigen-specific adaptive immune response and could 
contribute to parasite evasion of the host human system through subsequent 
lymphocyte exhaustion. In addition to this, a 1991 study found a factor 
released during experimental African Trypanosomiasis that triggers CD8+ T 
cell proliferation and production of IFN-γ, which has been suggested to be 
beneficial to parasite growth (Olsson et al. 1991) – this gives the impression 
that the parasites induce this response to benefit the progression of 
infection. However, within the literature, the use of different mouse strains 
and parasite strains has led to an incomplete story – standardizing 
experimental protocols would allow us to characterize the response to 
infection more clearly, and allow for the application of this knowledge to 
human infection and subsequent treatment.   
 
T cell activation during infection can lead to exhaustion, as noted in the 
introduction. The activation associated upregulation of inhibitory molecules 
such as PD-1 and LAG-3 has led to investigating blockade of these molecules 
in malarial infection as a therapy against blood stage malaria (Butler et al. 
2012). Due to similarities in the literature with trypanosome infection, it 
was decided to investigate the ability of PD-1 and LAG-3 blockade on the 
number of trypanosomes in the blood. This blocking of T cell exhaustion 
could hypothetically lead to a new avenue of treatment. 
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This chapter aims to further characterize the CD4+ cell response to 
trypanosome infection. Primarily we examine T cell activation, and then 
aimed to establish whether it is a strain specific response. We also tried to 
determine whether this activation was co-stimulation dependent through 
the blockade of CD28, and attempted to block the inhibitory T cell markers 
expressed during infection to determine what effect these have on infection 
and/or parasite survival. 
 
3.2 Trypanosome infection results in polyclonal CD4+ T cell activation 
Infection of mice with trypanosomes results in a massive proliferation of 
lymphocytes followed by lymphocyte exhaustion and consequent 
immunosuppression within the host. Characterising the CD4+ T cell response 
to trypanosome infection could help us to understand this response and 
potentially prevent the exhaustion and immunosuppression that follows – 
depending on the response this could also result in an option for treatment 
of infection.  
Unpublished work carried out in our lab by other scientists show a clear 
indication that experimental trypanosome infection in mice results in a 
polyclonal CD4+ T cell response.  
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Figure 4: Number of parasites per ml of blood during infection with 
Trypanosoma brucei brucei. Mice were infected with T.b.brucei strain 
TREU 927, culled at day 18. Data represents mean ± SD.  
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Infection of mice with Trypanosoma brucei brucei leads to an initial peak 
parasitemia of ~2 x 108 parasites/ml of blood at day 5 (Figure 4). Following 
this, the parasitemia appears to decrease, until day 14 which shows a small 
resurgence of parasite numbers. By the end of the experiment (day 18, 
figure 4), it appears as though the parasite numbers are increasing in the 
blood again, which could suggest a pattern of successive peaks of 
parasitemia which are characteristic of infection (Magez et al. 2008). 
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Figure 5: Infection with Trypanosoma brucei brucei leads to high percentages of 
CD4+ cells expressing activation markers such as ICOS and exhaustion markers 
such as PD-1 and LAG-3. Mice were infected with T.b.brucei strain TREU 927, 
culled at day 18, and their spleens and lymph nodes assessed for CD4+ cell 
activation. Mice also received intravenous injection of 1x106 D011.10 T cells to 
assess specificity of activated response. Data represents mean ± SEM.  
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Results show that infection with Trypanosoma brucei brucei results in 
activation of a large percentage of CD4+ T cells (Figure 5) – this is evident in 
the spleen where ICOS is expressed on roughly 90%, LAG-3 on 64%, and PD-1 
on 80% of CD4+ T cells at day 11. CD4+ T cells in the lymph nodes also 
express high levels of these markers – 30-40%, 16%, and over 30% of CD4+ T 
cells express ICOS, LAG-3, and PD-1 respectively at day 11 post infection 
(Figure 5). Such high numbers of activated CD4+ T cells are suggestive of a 
polyclonal, non-antigen-specific immune response, and as such, 1x106 
transgenic T cells with a receptor specific for OVA peptide were 
intravenously injected into mice. As the OVA peptide is not naturally 
expressed in mice, nor was it being introduced by experimental conditions, 
these cells should not be activated during the course of infection. Analysis 
of these OVA-specific T cells in lymph nodes (Figure 5) showed that 22-25% 
expressed ICOS, 17-40% expressed LAG-3, and 16-21% expressed PD-1, 
suggesting an activated phenotype in the absence of their cognate antigen. 
This would also indicate that the large percentages of CD4+ T cells we see 
activated through infection are activated regardless of their TCR specificity, 
in a polyclonal nature.  
 
3.3 Polyclonal CD4+ cell activation is not parasite-strain specific 
Following infection of mice with T.b.brucei TREU 927, other parasite strains 
were investigated in murine models, in order to characterize the response 
and to standardize experimental protocols while still being able to compare 
them to human infection.  
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At day 5 post-infection with STIB 247 (figure 6), a significant increase in 
CD4+ cells expressing ICOS is noted in infected mice when compared with 
the uninfected controls – a result previously noted during infection with 
TREU 927. Similarly, at day 11, the number of CD4+ cells expressing ICOS is 
again significantly increased in infected mice relative to the uninfected 
negative controls.  
 
In order to relate these results to a human infective strain of trypanosome, 
we decided then to investigate the CD4+ T cell response to a strain of 
Trypanosoma brucei gambiense. 
Figure 6: Infection with T. b. brucei strain STIB 247 results in large 
percentages of CD4+ cells becoming activated. Mice were infected with 
T.b.brucei 247, and culled at day 5 and day 11. Splenocytes were 
assessed for signs of CD4+ T cell activation through flow cytometry.  
Data represents mean ± SEM. * p<0.05, ** p<0.01, *** p<0.001, 
****p<0.0001 
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As with TREU 927 and STIB 247, infection of mice with T. b. gambiense leads 
to a large percentage of CD4+ cells being activated (Figure 7). Using an 
unpaired t test, it was determined that the expression of ICOS and LAG-3 on 
these CD4+ cells is significantly increased infected mice compared to naïve 
uninfected control mice. This suggests that the massive CD4+ T cell 
activation during infection is not specific to T. b. brucei, and could be found 
during human infection. 
 
3.4 Trypanosome infection causes CD28-dependent T cell activation 
Prolonged T lymphocyte activation has been considered as a prominent 
factor in the development and progression of rheumatoid arthritis, and from 
this theory Abatacept has been developed. A CTLA-4 fusion IgG, it binds 
with the B7 molecules on the APC, preventing ligation with the CD28 co-
stimulatory molecule on T cell surfaces (Moreland et al. 2006). We could 
therefore hypothesize that use of Abatacept would determine whether CD28 
signalling was important in the activation of T cells during trypanosome 
infection, and that this could shed some light upon the methods of immune 
system manipulation the parasite employs. This would help in the 
development of therapeutics aimed at halting this manipulation, and 
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Figure 7: Infection with T. b. gambiense results in the activation of 
large percentages of CD4+ cells. Mice were infected with T. b. 
gambiense strain PA44, and culled at day 11. The splenocytes were 
then assessed for CD4+ cell activation through flow cytometry as 
before. Data represents mean ± SEM. * p<0.05, ** p<0.01, *** p<0.001, 
****p<0.0001 
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allowing the immune system to mount the appropriate response to parasite 
infection.  
 
 
 
 
 
 
 
 
 
The number of parasites present per ml of blood primarily peaks at about 
day 4 in the groups of mice treated with either the isotype control fusion 
protein or the Abatacept (Figure 8). Untreated infected controls appear to 
have a peak parasitemia a day later than treatment groups, at day 5 as we 
saw in previous T. b. brucei TREU 927 infections (Figure 4). Abatacept 
treated mice show a low to undetectable level of blood parasitemia at day 
11, which is lower than both the untreated infected mice and the isotype 
control treated mice – however this difference is only noticeable at day 11, 
and is not a significant difference. A longer experiment might result in a 
more significant difference in parasitemia between the groups, however the 
parasitemia levels in the isotype control would have to be taken into 
consideration, as they are noticeably higher and showed an increased 
secondary peak of parasitemia when compared with the other experimental 
groups.  
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Figure 8: Number of parasites per ml of blood during infection with 
Trypanosoma brucei brucei. Mice were infected with T.b.brucei strain 
TREU 927, and separated into groups dependent on treatment status. 
Mice were intraperitoneally injected every second day from day -1 with 
10mg/kg Abatacept or a control fusion protein acting as an isotype 
control. Mice were culled at day 11 and their spleens removed and 
analysed for CD4+ cell activation through flow cytometry. Data 
represents mean ± SD.  
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As previously noted, infection resulted in an increased expression of ICOS on 
CD4+ T cells when compared with uninfected mice (Figure 9). Infected mice 
Figure 9: Infection with Trypanosoma brucei brucei leads to high 
percentages of CD4+ cells expressing activation markers such as ICOS and 
exhaustion markers such as PD-1 and LAG-3. Mice were separated into 
groups based on treatments and infection status. Treated mice were 
intraperitoneally injected every second day from day -1 with 10mg/kg 
Abatacept or a control fusion protein acting as an isotype control. Mice 
were infected with T.b.brucei strain TREU 927, culled at day 11, and 
their spleens assessed for CD4+ cell activation.  Abatacept treatment 
lessens the expression of PD-1 and ICOS in infected mice relative to their 
untreated counterparts. Data represents mean ± SEM. All pairwise 
comparisons were tested for significance; only those with a significance 
of p<0.05 are annotated. * p<0.05, ** p<0.01, *** p<0.001, ****p<0.0001 
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treated with Abatacept showed a significant decrease in the expression of 
ICOS in splenic CD4+ cells when compared with the untreated infected 
group (Figure 9). The expression of LAG-3 appeared to be lower in infected 
mice than we expected and was not significantly different from the 
uninfected mice - except in the case of the Abatacept treated infected 
mice, which was significantly higher than the naïve mouse controls (Figure 
9). Expression of PD-1 was increased significantly in infected mice relative 
to the uninfected controls. Abatacept treatment results in a decrease in the 
expression of PD-1 in infected mice, however this is not significant from the 
untreated counterpart groups (Figure 9).  
 
3.5 Does blockade of exhaustion molecules restore CD4+ T cell 
functionality? 
As seen in the Butler paper (Butler et al. 2012), blockade of exhaustion 
markers PD-1 and LAG-3 during murine infection with Plasmodium yoelli 
lead to clearance of the blood stage infection. Given that during infection 
with Trypanosoma species T cells become exhausted, we hypothesized that 
something similar may occur were these markers to be blocked.  
Treatment groups in the in vivo experiment included untreated, isotype 
control treated, and combined anti-PD-L1 and anti-LAG-3 antibody 
treatment. Mice were infected with T. b. brucei reference strain TREU 927 
and treated with every third day from day 4 post-infection. Mice were 
culled at day 14 and their spleens assessed for CD4+ cell activation status. 
They were also assessed for blood parasitemia on a daily basis. 
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Blood parasitemia was assessed daily in each treatment group in order to 
ascertain what effect inhibitory marker blockade would have on the number 
of blood parasites. As seen in Figure 10, the first peak of parasitemia in 
mice occurred at days 4-5. Following the subsequent rapid decline, the 
parasites increase in number from day 7 onwards. Isotype control treated 
mice showed a higher blood parasitemia on the cull day (day 14) than either 
the untreated or the inhibitory blockade treated animals (Figure 10), both 
of which appeared to have a similar level of blood parasitemia (~100x106 
parasites/ml of blood). 
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Figure 10: Treatment with anti-PD-L1 and anti-LAG-3 during T. b. 
brucei infection does not clear parasites from the blood. Mice were 
infected intraperitoneally with T. b. brucei TREU 927. Treatment was 
administered every 2 days from day 5 post-infection – 200µg of each 
anti-mouse LAG-3 and anti-mouse PD-1 were administered in 200µl via 
intraperitoneal injection in anti-LAG-3 and anti-PD-1 treated mice, 
while 200µg of Rat IgG was administered in 200µl via intraperitoneal 
injection in the isotype control treated mice. Mice were culled at day 
14, their spleens were harvested and assessed for signs of CD4+ T cell 
activation by flow cytomtery. Data represents mean ± SD.  
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As we have previously seen, infection with trypanosomes induces a 
significant increase in the expression of ICOS and PD-1, which we see here 
again in Figure 11. LAG-3 expression was again not significantly changed 
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Figure 11: The effect of treatment with anti-PD-L1 and anti-LAG-3 on 
CD4+ T cell activation and exhaustion markers during infection. Mice 
were infected intraperitoneally with T. b. brucei TREU 927. Treatment 
was administered every 2 days from day 5 post-infection – 200µg of 
each anti-mouse LAG-3 and anti-mouse PD-1 were administered in 200µl 
via intraperitoneal injection in anti-LAG-3 and anti-PD-1 treated mice, 
while 200µg of Rat IgG was administered in 200µl via intraperitoneal 
injection in the isotype control treated mice. Mice were culled at day 
14, their spleens were harvested and assessed for signs of CD4+ T cell 
activation by flow cytomtery. Data represents mean ± SEM. * p<0.05, ** 
p<0.01, *** p<0.001, ****p<0.0001  
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during this infection – as we have seen it significantly increased previously, 
we could hypothesize that there has been a problem with staining that 
particular marker, or using that particular antibody.  
ICOS expression on CD4+ T cells following treatment with anti-LAG-3 and 
anti-PD-1 remains similar to that in untreated infection, suggesting that 
blocking these markers does not impact upon activation status of the CD4+ T 
cells. PD-1 expression however, is significantly increased in treated mice 
compared to untreated or isotype control treated mice (Figure 11). 
 
3.5 Discussion of Results 
Using Balb/c mice and T. b. brucei strains, work carried out in this chapter 
shows that large percentages of CD4+ cells are activated during infection 
with these parasites (Figure 4 and Figure 5). These large percentages of 
activated cells suggest activation of a polyclonal nature – that is, T cells are 
being activated regardless of antigenic specificity. This was confirmed 
through use of transgenic T cells specific to OVA peptide – these cells were 
activated during trypanosome infection despite the absence of their cognate 
antigen, suggesting that the method by which trypanosomes activate CD4+ T 
cells is non-antigen specific, causing inflammation that could result in 
damage to host tissue.  
 
In order to further study CD4+ cell response to trypanosome infection, it 
was important to determine whether this response was specific to one strain 
of parasite. This would help us to standardize experimental protocols and 
would also help us to relate experimental models to human infection. TREU 
927 is a difficult strain to culture in laboratory conditions, and so it was 
decided to test the CD4+ cell response to strain STIB 247 (Figure 6). This 
strain, as well as being easier to culture in the lab, is easier to genetically 
manipulate, which would be advantageous in the elucidation of the 
mechanisms by which trypanosomes manipulate host immune cells. At both 
days 5 and 11 post-infection, ICOS expression was significantly increased 
(p<0.0001) in infected mice relative to the uninfected controls (Figure 6). 
This increase was also noted to be significant in LAG-3 expression at day 5 
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(p<0.0001) and PD-1 expression at day 11 (p<0.01). As with previous data 
using T. b. brucei TREU 927, this suggests that T. b. brucei STIB 247 
activates CD4+ T cells in large numbers, and would also indicate that this 
phenomenon is not parasite strain specific. This would be beneficial in 
future studies, both for use of parasites in in vitro models, and through use 
of genetic knock out parasites in vivo.  
 
As with our STIB 247 work, assessment of the ability of T. b. gambiense to 
provoke a polyclonal CD4+ cell activation was carried out. T. b. gambiense  
has been described in this thesis as one of the two human infective 
trypanosomes, and so establishing its ability to activate CD4+ cells could 
have an effect on the investigation and treatment of human African 
trypanosomiasis. In figure 7, it is shown that ICOS expression and LAG-3 
expression is increased significantly (p<0.001, p<0.01 respectively) in 
infected mice when they are compared with the uninfected control group, 
indicating that the human infective parasite has a similar effect as the T. b. 
brucei strains we have investigated prior to this.  
 
Due to the multi-step nature of T cell activation discussed in the 
introduction, further investigation could elucidate which step(s) the 
trypanosomes manipulate in order to promote this response. Keeping this in 
mind, use of Abatacept, a drug which prevents the CD28 co-stimulatory 
signal occurring in T cells, has revealed that this activation is partially 
CD28-dependent – in the case of both ICOS and PD-1, both markers were 
significantly reduced in Abatacept treated mice compared to their 
untreated infected counterparts. This suggests that the costimulatory T cell 
activation signal is important in propagating this response to trypanosome 
infection. However, LAG-3 staining seems in this instance to have possibly 
been aberrant – we might have expected LAG-3 expression to be 
significantly higher in infected mice than uninfected mice, however this was 
only true of the Abatacept treated mice. It is possible that LAG-3 is not up-
regulated in infection, however previous work in the lab has indicated 
otherwise and would therefore suggest that there was an operator error or 
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problem with the reagent. Through the significant increase of ICOS and PD-1 
expression in CD4+ cells during trypanosome infection (both p<0.0001, seen 
in Figure 9), we can note that high percentages of CD4+ cells are activated 
and display exhaustion markers following trypanosome infection. It can also 
be observed that use of Abatacept reduces the expression of both of these 
markers - ICOS expression reduced significantly (p<0.0001), and PD-1 
reduced, however not significantly. This would imply that the method of 
activation of CD4+ cells during trypanosome infection involves use of the 
CD28 co-stimulatory signaling pathway. Interestingly, the number of 
parasites present in the blood at day 11 following Abatacept treatment is 
low to undetectable (Figure 8), where the untreated and isotype control 
treated maintain a detectable parasite level. As previously stated, this is 
not a significant result, and no real conclusions can be drawn from this. 
However, if further investigation shows this to be a true result, this could 
suggest that blocking CD4+ T cell activation could result in the clearance of 
the parasites from the blood. A repeat of this experiment with a possible 
longer time line involving Abatacept treatment would be required to prove 
any significant impacts of Abatacept treatment on blood parasitemia. As 
well as this, the isotype control treated mice (Figure 8) had a much higher 
secondary peak of parasitemia at day 10 – this could maybe point towards 
an inflammatory response to the control fusion protein resulting in a higher 
blood parasitemia. 
 
Finally, having read in the literature available that blockade of inhibitory 
receptors lead to a clearance of parasites within the blood during malarial 
infection (Butler et al. 2012), we hypothesized that something similar may 
be happening during trypanosome infection. As such, we decided to block 
the inhibitory receptors PD-1 and LAG-3, and assessed the blood parasite 
burden on a daily basis. Antibody treatment was given from day 4 post-
infection, and did not seem to clear parasites from the blood (Figure 10). 
The second peak of parasitemia for treated mice appeared to be lower than 
untreated and isotype treated controls, however by the time of the cull on 
day 14, the treated mice had blood parasite numbers comparable to that of 
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the untreated mice (100 x 106 parasites/ml of blood). One reason behind not 
seeing clearance of parasites could be that the infection needs to progress 
further, and the mice culled at a later date. This could also apply to the 
CD4+ T cell functionality following treatment – the effects of anti-PD-1 and 
anti-LAG-3 treatment which were noted during infection with P. yoelli 
(Butler et al. 2012) were seen during a longer term infection (34 days) than 
the one we carried out. As such, while we cannot say now that the antibody 
treatment results in blood parasite clearance or affects CD4+ T cell 
functionality, it may well do so further along in the infection, and it may 
therefore be beneficial to carry out a longer-term infection model. 
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Chapter 4: Results – Developing an in vitro assay which reproduces the 
CD4+ T cell activation seen in vivo 
4.1 Introduction and Aims 
In order to better elucidate the mechanisms underlying the polyclonal T cell 
activation observed during trypanosome infection in vivo I decided to 
develop an in vitro assay. This reductionist approach would allow me to test 
and manipulate both host and parasite components under carefully 
controlled and relatively high throughput in vitro conditions before going on 
to confirm them in more complex, lengthy, and expensive in vivo systems. I 
initially started with splenocytes with the intention of progressing to 
defined T cell and APC populations.  
Similarly, I aimed to optimize the system using live parasites before 
progressing to parasite extracts and molecules and genetically manipulated 
parasites. The mechanism by which trypanosomes activate T cells 
polyclonally is unclear, and could occur by direct interaction of parasites or 
parasite secretions upon the T cells, or through other indirect mechanisms. 
An in vitro assay will allow us to assess each possibility quickly and 
inexpensively. 
 
4.2 Live, Lysed and Ex Vivo parasites do not induce CD4+ T cell 
activation in vitro 
In order to assess the effect of live, cultured STIB 247 trypanosomes on 
CD4+ cells, splenocytes were cultured with trypanosomes for up to 48 hours. 
A range of parasite numbers was also used, in order to determine an optimal 
number of trypanosomes for future experiments. The T cell mitogen 
concanavalin A (ConA, 2.5µg/ml) was used as a positive control (Lopes & Dos 
Reis 1994).  
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ConA stimulation resulted in an increased expression of ICOS and LAG-3 on 
live CD4+ splenocytes after 72 hours co-culture, which indicates an 
activated phenotype. However, as seen in Figure 12, all live trypanosome 
co-cultures showed no increase in expression of either of these cell markers, 
suggesting that live trypanosomes alone do not activate CD4+ T cells. The 
experiment was only performed once and does not have any replicates with 
which to perform statistical analysis at this point. Parasites were live and 
appeared healthy at all time points during the experiment, as assessed by 
light microscopy. At 72 hours the number of splenocytes in culture seemed 
to be decreased, and the media had yellowed, suggesting cellular death 
leading to acidification of the media. This can also occur in response to 
overgrowth of cells leading to the depletion of nutrients within the media – 
however fewer splenocytes were seen at this time point, implying this was 
not the case. Live parasites do not appear therefore to promote 
proliferation of parasites in vitro. At this point, we decided to modify the 
media to allow for further cell survival and proliferation - specifically we 
added supplementary glucose, bringing the final concentration of the media 
to 4.5g/L, as trypanosomes are high metabolisers of glucose (Haanstra et al. 
2014). 
 
Figure 12: Live trypanosomes do not induce CD4+ lymphocyte 
activation. ICOS (left) and LAG-3 (right) expression following co-culture 
with 103, 104 and 105 trypanosomes was assessed on live CD4+ 
lymphocytes through flow cytometry.  
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As live trypanosomes did not induce CD4+ T cell activation, lysed 
trypanosomes were next investigated, in case the trypanosomal component 
involved is not secreted by the parasites, and must be released upon death 
or lysis. Again, ConA (2.5µg/ml) was used as a positive control, and 
parasites were lysed through a number of freeze-thaw cycles over a period 
of six hours. However, again it was noted that while ConA stimulated cells 
showed an increase in the expression of ICOS and LAG-3, cells cultured with 
the lysates of 105 parasites showed no significant upregulation of these 
markers, implying that lysed trypanosomes also do not activate CD4+ T cells 
(Figure 13).   
Figure 13: Lysed trypanosomes do not induce CD4+ lymphocyte 
actiation. Splenocytes were cultured with the lysate of 105 
trypanosomes and cultured for up to 72 hours. Percentage of live CD4+ 
lymphocytes expressing ICOS (left) and LAG-3 (right) was assessed 
through flow cytometry. The experiment was performed once and has 
no replicates available for statistical analysis 
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Following the previous results, we considered the idea that the cultured 
parasites had adapted to culture, losing some of their ability to induce CD4+ 
T cell activation. Therefore, examination of the effect of ex vivo parasites 
upon CD4+ T cell activation was carried out (Figure 14). Blood was extracted 
from an infected Balb/c mouse, and the parasites were collected by 
centrifugation and added to splenocytes in vitro at a concentration 105 
parasites per well. As before, 2.5µg/ml ConA was used as a positive control. 
As seen in previous experiments, the expression of ICOS and LAG-3 on CD4+ 
cells was upregulated in response to ConA stimulation, but remained similar 
to the negative control in the splenocyte and trypanosome co-culture wells. 
This, along with the previous two experiments, suggests that trypanosomes 
alone, whether live, lysed, or ex vivo, cannot induce the polyclonal CD4+ T 
cell activation that we have witnessed in vivo.  
 
  
Figure 14: Ex vivo trypanosomes do not induce CD4+ lymphocyte 
activation. Trypanosomes were extracted from an infected Balb/c 
mouse 5 days following infection. Naïve splenocytes were then co-
cultured with 105 trypanosomes and cultured for 72 hours. ICOS (left) 
and LAG-3 (right) expression following co-culture was assessed on live 
CD4+ lymphocytes through flow cytometry 
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4.3 CD4+ T cell activation persists ex vivo for up to 72 hours 
It remained possible that failure to reproduce in vivo CD4+ T cell activation 
in response to trypanosomes in vitro could be due to lack of an 
environmental factor in culture. In order to examine this possibility, 
splenocytes were taken from an infected mouse as opposed to a naïve, 
uninfected mouse, and cultured in vitro for 72 hours.  
 
We expected to see CD4+ cell activation at 0 hours ex vivo, and we 
hypothesized that if an environmental factor present in the live animal but 
not in in vitro culture was required to maintain the CD4+ T cell activation, 
we would see the CD4+ cell activation decrease in culture. Keeping this in 
mind, we noted that following extraction of splenocytes from the infected 
mouse, CD4+ cell activation (as measured by ICOS and LAG-3 upregulation) 
remained consistently and significantly higher than in the negative controls 
for up to 72 hours (Figure 15). This would suggest that our in vitro assay 
does not currently include a key component of the initial activation, 
however it does allow for sustained activation of CD4+ cells. 
 
4.4 Trypanosomes can enhance Con A mediated activation of CD4+ T 
cells in vitro 
As previously discussed, the ability of ex vivo infected splenocytes to retain 
CD4+ cell activation could be due to the initial activation signal having 
occurred in vivo, starting the chain of events. To test the hypothesis that an 
Figure 15: Activation of CD4+ lymphocytes during T.b.brucei infection 
persists ex vivo for up to 72 hours. Infected splenocytes were extracted 
5 days post infection of Balb/c mice, and cultured in vitro for 72 hours. 
Cells were assessed for expression of ICOS (left) and LAG-3 (right) by 
flow cytometry at 24 hour time points. 
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initial signal absent from our in vitro cultures is required to work in tandem 
with the parasite in order to promote CD4+ T cell activation, sub-optimal 
levels of ConA (0.1µg/ml) were added to trypanosome and splenocyte co-
cultures. These levels of ConA are sub-optimal for CD4+ T cell activation on 
its own, which is seen in Figure 16, but when added to splenocytes with 
cultured trypanosomes, an upregulation of both ICOS and LAG-3 can be seen 
96 hours later, indicating CD4+ T cell activation.  
 
 
This is consistent with the result seen in a study of Trypanosoma cruzi 
infection (Gao & Pereira 2001), in which the authors noted that ConA and 
Trypanosoma cruzi parasites act in tandem to promote T cell activation and 
proliferation.  
 
  
Figure 16: Presence of sub-optimal levels of ConA during trypanosome 
and splenocyte co-culture results in activation of CD4+ cells in vitro 
after 96 hours in culture. Naïve splenocytes were cultured in the 
presence of 105 parasites and 0.1µg/ml ConA for up to 96 hours. Cells 
were then assessed for levels of ICOS and LAG-3 expression by flow 
cytometry. Data represents mean ± SD. * p<0.05, ** p<0.01, *** 
p<0.001, ****p<0.0001 
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4.5 Discussion of Results 
In this chapter I have begun to develop an in vitro assay to replicate the in 
vivo conditions seen in response to T. b. brucei infection.  
 
From our development of an in vitro assay, we discovered that T. b. brucei 
parasites alone, whether they are live, lysed, or ex vivo, do not directly 
activate T cells in the polyclonal manner that we have come to expect both 
from the literature and from our in vivo observations. This hinted towards 
there being an indirect mechanism, or a synergistic route by which CD4+ T 
cells are activated in vivo.  
 
Keeping this in mind, we found that parasites in the presence of a low level 
of mitogenic ConA results in a synergistic effect on CD4+ cells and promotes 
their activated phenotype. This had been shown to be the case in T. cruzi in 
a study by Gao & Pereira (Gao & Pereira 2001), however this had not been 
shown to be the case in T. b. brucei until now. Within this study, the 
authors also discuss a neuraminaidase expressed by T. cruzi that may be the 
potentiator of lymphocyte activation during infection. This neuraminidase, 
called trans-sialidase, is also expressed in T. b. brucei, and could therefore 
be the cause of lymphocyte activation during this infection. Further testing 
will have to be carried out in order to confirm this hypothesis. This assay 
could therefore be used to test for which T. b. brucei derived genes can 
activate CD4+ T cells in this manner – as noted formerly trans-sialidase 
would perhaps be a good place to start testing.  
Discovering the mechanism by which trypanosomes activate T lymphocytes 
could have implications on the development of future treatments through 
an increased understanding of the polyclonal activation of T cells during 
infection, and the potential manipulation of this interaction.  	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Chapter 5: Results – Conclusions and Future Perspectives 
 
In this thesis I aimed to further investigate the CD4+ T cell response to 
trypanosome infection. Two routes of investigation were used – the in vivo 
infection of mice and the in vitro assay development. Through in vivo work 
we have shown that large percentages of T cells are activated during 
infection with Trypanosoma brucei brucei and Trypanosoma brucei 
gambiense, and that this activation is polyclonal in nature, resulting in 
exhaustion of lymphocytes. This exhaustion partially contributes to the 
immunosuppression characteristic of trypanosome infection, and so 
understanding how it is initiated is crucial to the development of 
therapeutics manipulating this response in order to protect the host. With 
this in mind we also demonstrated through the use of Abatacept that this 
activation is dependent in part on CD28 signalling. The lower number of 
blood parasites present in mice following Abatacept treatment, if 
significant, could potentially indicate a link between T cell activation and 
the location of parasites within the host, and this could in turn explain both 
the presence of asymptomatic patients within the human population 
(Jamonneau et al. 2012) and the persistence of infection despite drug 
treatment and vector control. However, as previously discussed, this would 
need to be further investigated. 
 
The work carried out in this thesis has also shown, through the development 
of an in vitro assay, that this activation occurs in response to trypanosomes 
in tandem with another activating signal, such as in the case of T. cruzi 
(Gao & Pereira 2001). The development of a working in vitro assay means 
that future work can involve testing candidate T cell activating trypanosome 
genes, through the use of knock out parasites and RNAi libraries, allowing 
for validation of theories before the expensive and time consuming in vivo 
models. This could lead to the elucidation of the genetic mechanism of 
trypanosome immune manipulation, and would also allow research into how 
to stop this effect during infection. This could lead to a more targeted 
therapeutic approach to the eradication of HAT and Nagana. 
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In this thesis, we also used antibodies to block LAG-3 and PD-1, both 
markers of T cell exhaustion, and hypothesized that this would have some 
effect on the number of parasites in the blood of the host. However, this 
was not the case for our experiment – there was no clearance of parasites 
from the host blood, and it seemed little effect was had upon CD4+ T cell 
functionality. It might be advantageous to see a longer-term infection, and 
the effect that these antibodies would have there, and to assess the 
presence of cytokines or chemokines associated with activation to 
determine lymphocyte functionality further.  
 
This thesis has described CD4+ T cell response to trypanosome infection, 
both in murine infection models and in vitro assay development. With 
trypanosomes actively evading and suppressing the immune response in both 
humans and other mammalian infections, it is crucial to the development of 
new therapeutics that we seek to understand and characterize these 
responses.  
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